Evidence map›Paper›PMID 41569354›Full record

ArticleClinical rheumatology2026

Telitacicept for childhood HSPN: A prospective self-controlled study.

Hanhan Zhang, Dan Song, Ke Song, Chundong Song, Xiaoxiao Guo, Chenchen Chen, Caixia Jiang, Ying Ding, Mo Wang, Junjun Zhang

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hanhan ZhangPediatric Nephrology and Purpura Center, Children's Hospital, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China.
Dan SongGraduate School, Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China.
Ke SongPediatric Nephrology and Purpura Center, Children's Hospital, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China.
Chundong SongPediatric Nephrology and Purpura Center, Children's Hospital, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China. s023023@126.com.ORCID http://orcid.org/0009-0009-8589-1917
Xiaoxiao GuoPediatric Nephrology and Purpura Center, Children's Hospital, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China.
Chenchen ChenPediatric Nephrology and Purpura Center, Children's Hospital, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China.
Caixia JiangPediatric Nephrology and Purpura Center, Children's Hospital, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China.
Ying DingPediatric Nephrology and Purpura Center, Children's Hospital, the First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, Henan, 450000, China.
Mo WangDepartment of Nephrology and Immunology, Children's Hospital of Chongqing Medical University, Chongqing, 400014, China.
Junjun ZhangDepartment of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450000, China.

Funding

Health Commission of Henan Province 2022JDZX003Health Commission of Henan Province 2024ZY1002National Natural Science Foundation of China No.82074493Natural Science Foundation of Henan Province No.202300410266other NO. 2023ZYZD02other No. YUWMZYH [2021] No. 8other RCTAIIRHSPN001
6 · The paper itself

Abstract

objectivesTo investigate the efficacy and safety of Telitacicept (RC18) in children with Henoch-Schönlein Purpura Nephritis (HSPN).

methodsA prospective self-controlled study enrolled HSPN children from the First Affiliated Hospital of Henan University of Chinese Medicine from December 2023 to January 2025. Clinical and laboratory indices and adverse reactions were recorded during 1-4 months of follow-up. Primary study endpoint was 24 h UTP, and the secondary study endpoints included urinary RBC count, renal function (BUN, UA, Scr, eGFR) and safety. Exploratory analysis included dynamic changes in lymphocytes, BAFF, APRIL and Gd-IgA1.

resultsTwenty-one patients were enrolled. After Telitacicept treatment, the 24 h UTP response rate was 100%, and urine RBC response rate was 66.7%. Renal function remained stable. Compared with baseline, 24 h UTP values and the reduction rate were significantly decreased at 4 months (P < 0.01), and urinary RBC count was significantly decreased at 3 months (P < 0.01). Exploratory analyses showed that the percentage of CD19 + decreased, while there was no decrease in CD3 + , CD3 + CD4 + , and CD3 + CD8 + cells. Meanwhile, the Gd-IgA1 level trended downward. Safety assessment demonstrated no serious adverse reactions, with abnormalities observed in biochemical parameters (ALT: 4.8%; UA: 19.0%) and injection site reactions (14.3%).

conclusionRC18 effectively reduces urine protein and RBC in HSPN children, with good clinical effects and safety. Key Points • Efficacy and safety study of Telitacicept in the treatment of children with HSPN. • Preliminary exploration on the mechanism of Telitacicept in the treatment of children with HSPN.

Indexed as

IgA VasculitisNephritisAdolescentChildChild, PreschoolFemaleHumansMaleProspective StudiesRecombinant Fusion ProteinsTreatment OutcomeRecombinant Fusion ProteinstelitaciceptChildrenEfficacyHenoch-Schönlein purpura nephritisSafetyTelitacicept

Identifiers

PMID41569354

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.